1
|
Wang Q, Liu Z. Recent progress of surface plasmon resonance in the development of coronavirus disease-2019 drug candidates. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY REPORTS 2021; 1:100003. [PMID: 36304139 PMCID: PMC8237387 DOI: 10.1016/j.ejmcr.2021.100003] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 06/21/2021] [Accepted: 06/24/2021] [Indexed: 01/07/2023]
Abstract
At the end of 2019, the new coronavirus caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) suddenly raged, bringing a severe public health crisis to the world. It is urgent to discover suitable drugs and treatment regimens against this coronavirus disease 2019 (COVID-19) and related diseases. Based on the previous knowledge and experience in treating similar diseases, researchers have come up with hundreds of possible drug candidates in the shortest possible time. Based on surface plasmon resonance (SPR) technology, this review summarized the application of SPR technology in COVID-19 research from four aspects: the invasion mode of SARS-CoV-2 into host cells, antibody drug candidates for the treatment of COVID-19, small molecule drug repurposing and vaccines for COVID-19. SPR technology has gradually become a powerful tool to study the interaction between drugs and targets due to its high efficiency, automation, labeling-free and high data resolution. The use of SPR technology can not only obtain the affinity data between drugs and targets, but also clarify the binding sites and mechanisms of drugs. We hope that this review can provide a reference for the subsequent application of SPR technology in antiviral drug development.
Collapse
Affiliation(s)
- Qian Wang
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China
| | - Zhenming Liu
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China
| |
Collapse
|
2
|
Wang Q, Zhu G, Liu Z. Establishment of inhibitor screening and validation system for tryptophanyl tRNA synthetase using surface plasmon resonance. Anal Biochem 2021; 623:114183. [PMID: 33798474 DOI: 10.1016/j.ab.2021.114183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2020] [Revised: 03/17/2021] [Accepted: 03/20/2021] [Indexed: 11/28/2022]
Abstract
With the increase in throughput and sensitivity, biophysical technology has become a major component of the early drug discovery phase. Surface plasmon resonance technology (SPR) is one of the most widely used biophysical technologies. It has the advantages of circumventing labeling, molecular weight limitations, and neglect of low affinity interactions, etc., and provides a robust platform for hit to lead discovery and optimization. Here, we successfully established a reliable and repeatable tryptophanyl tRNA synthetase (TrpRS) SPR high-throughput screening and validation system by optimizing the TrpRS tag, TrpRS immobilization methodology, and the buffer conditions. When TrpRS was immobilized on Streptavidin (SA) sensor chip, the substrate competitive inhibitor indolmycin exhibited the best binding affinity in HBS-P (10 mM HEPES, 150 mM NaCl, 0.05% surfactant P-20, pH 7.4), 1 mM ATP and MgCl2, with a KD (dissociation equilibrium constant) value of 0.6 ± 0.1 μM. The Z-factor values determined in the screening assays were all larger than 0.9. We hope that our proposed research ideas and methods may provide a scientific basis for establishing SPR analysis of other drug targets, accelerate the discovery and optimization of target lead compounds, and assist the clinical application of next-generation drugs.
Collapse
Affiliation(s)
- Qian Wang
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
| | - Guiwang Zhu
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
| | - Zhenming Liu
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
| |
Collapse
|
3
|
Yang Z, Wang Y, Zhang L, Zhao C, Wang D. Phosphorylated form of pyruvate dehydrogenase α1 mediates tumor necrosis factor α-induced glioma cell migration. Oncol Lett 2021; 21:176. [PMID: 33574915 PMCID: PMC7816412 DOI: 10.3892/ol.2021.12437] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2020] [Accepted: 10/20/2020] [Indexed: 12/20/2022] Open
Abstract
Cell migration is an important factor influencing the treatment outcomes of high-grade glioma (World Health Organization grades III–IV). Using immunohistochemical staining, the present study demonstrated that the protein levels of phosphorylated pyruvate dehydrogenase α1 (p-PDHA1) were increased according to the grade of glioma. Moreover, p-PDHA1 mediated tumor necrosis factor-α (TNF-α)-induced cell migration in glioma cells. Phalloidin staining and western blot analysis were used to detect the protein level of p-PDHA1 in U251 glioma cells stimulated by TNF-α at different time points. Phalloidin staining was used to observe the cytoskeletal structure. The effects on the expression of specific migration markers and on the cytoskeletal structure were also detected. Dichloroacetic acid is an inhibitor of PDK. These results indicated that p-PDHA1 served an important role in the migration of glioma cells, and consequently in the development of glioma.
Collapse
Affiliation(s)
- Zijun Yang
- Department of Pathology, Medical College, Nantong University, Nantong, Jiangsu 226002, P.R. China
| | - Yidan Wang
- Center for Health Management, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226002, P.R. China
| | - Li Zhang
- Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Medical College, Nantong University, Nantong, Jiangsu 226002, P.R. China
| | - Chenjin Zhao
- Department of Cerebral Surgery, The Second People's Hospital of Nantong, Nantong, Jiangsu 226002, P.R. China
| | - Donglin Wang
- Department of Pathology, Medical College, Nantong University, Nantong, Jiangsu 226002, P.R. China
| |
Collapse
|
4
|
Fischer R, Kontermann RE, Pfizenmaier K. Selective Targeting of TNF Receptors as a Novel Therapeutic Approach. Front Cell Dev Biol 2020; 8:401. [PMID: 32528961 PMCID: PMC7264106 DOI: 10.3389/fcell.2020.00401] [Citation(s) in RCA: 123] [Impact Index Per Article: 30.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2020] [Accepted: 05/01/2020] [Indexed: 12/14/2022] Open
Abstract
Tumor necrosis factor (TNF) is a central regulator of immunity. Due to its dominant pro-inflammatory effects, drugs that neutralize TNF were developed and are clinically used to treat inflammatory and autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. However, despite their clinical success the use of anti-TNF drugs is limited, in part due to unwanted, severe side effects and in some diseases its use even is contraindicative. With gaining knowledge about the signaling mechanisms of TNF and the differential role of the two TNF receptors (TNFR), alternative therapeutic concepts based on receptor selective intervention have led to the development of novel protein therapeutics targeting TNFR1 with antagonists and TNFR2 with agonists. These antibodies and bio-engineered ligands are currently in preclinical and early clinical stages of development. Preclinical data obtained in different disease models show that selective targeting of TNFRs has therapeutic potential and may be superior to global TNF blockade in several disease indications.
Collapse
Affiliation(s)
- Roman Fischer
- Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany
| | - Roland E Kontermann
- Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany
| | - Klaus Pfizenmaier
- Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany
| |
Collapse
|
5
|
Yang W, Zhang Q, Zhang C, Guo A, Wang Y, You H, Zhang X, Lai L. Computational design and optimization of noveld‐peptideTNFα inhibitors. FEBS Lett 2019; 593:1292-1302. [DOI: 10.1002/1873-3468.13444] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2019] [Revised: 04/27/2019] [Accepted: 05/14/2019] [Indexed: 01/18/2023]
Affiliation(s)
- Wei Yang
- School of Life Sciences Tsinghua University Beijing China
| | - Qi Zhang
- School of Life Sciences Peking University Beijing China
- Peking‐Tsinghua Center for Life Sciences AAIS Peking University Beijing China
| | - Changsheng Zhang
- BNLMS College of Chemistry and Molecular Engineering Peking University Beijing China
| | - Annan Guo
- Peking‐Tsinghua Center for Life Sciences AAIS Peking University Beijing China
| | - Yanyan Wang
- Peking‐Tsinghua Center for Life Sciences AAIS Peking University Beijing China
| | - Hantian You
- BNLMS College of Chemistry and Molecular Engineering Peking University Beijing China
| | - Xiaoling Zhang
- Center for Quantitative Biology AAIS Peking University Beijing China
| | - Luhua Lai
- Peking‐Tsinghua Center for Life Sciences AAIS Peking University Beijing China
- BNLMS College of Chemistry and Molecular Engineering Peking University Beijing China
- Center for Quantitative Biology AAIS Peking University Beijing China
| |
Collapse
|
6
|
Liu H, Liang H, Meng H, Deng X, Zhang X, Lai L. A novel allosteric inhibitor that prevents IKKβ activation. MEDCHEMCOMM 2018; 9:239-243. [PMID: 30108917 DOI: 10.1039/c7md00599g] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/25/2017] [Accepted: 01/05/2018] [Indexed: 12/23/2022]
Abstract
I kappa B kinase β (IKKβ) is one of the primary targets to regulate canonical NF-κB activity. The misregulation of NF-κB is associated with various diseases, including chronic inflammation and cancers. Most of the known IKKβ inhibitors target its active form and suffer from poor selectivity. In the present study, we aim to design inhibitors that can bind to the IKKβ inactive form and block its activation. We identified a potential allosteric site between the kinase domain (KD) and ubiquitin-like domain (ULD) of human IKKβ and used it to virtually screen a chemical library for allosteric inhibitors. Among the 133 compounds tested, 16 inhibited NF-κB activity by over 50% at 50 μM in a reporter gene assay. Further quantitative measurements and cytotoxicity study gave one compound 124 (3,4-dichloro-2-ethoxy-N-(2,2,6,6-tetramethylpiperidin-4-yl)benzenesulfonamide) which specifically targets the IKKβ inactive form. In cells, 124 inhibited IκBα phosphorylation and NF-κB transcriptional activity for the reporter gene with an IC50 of 35 μM by decreasing the phosphorylation level of Ser177/181 on IKKβ and blocking its activation upon TNFα stimulation. Molecular dynamics simulations demonstrated that 124 binds to the pocket between KD and ULD in the inactive conformation of IKKβ rather than the active conformation. As the first allosteric inhibitor that prevents IKKβ activation, 124 provides a good starting point for further inhibitor discovery and a probe for IKKβ enzyme cycle and regulatory mechanism study.
Collapse
Affiliation(s)
- Hongbo Liu
- Peking-Tsinghua Center for Life Sciences , Peking University , Beijing 100871 , China .
| | - Hao Liang
- Peking-Tsinghua Center for Life Sciences , Peking University , Beijing 100871 , China .
| | - Hu Meng
- BNLMS , State Key Laboratory for Structural Chemistry of Unstable and Stable Species , College of Chemistry and Molecular Engineering , Peking University , Beijing 100871 , China
| | - Xiaobing Deng
- Peking-Tsinghua Center for Life Sciences , Peking University , Beijing 100871 , China .
| | - Xiaoling Zhang
- Center for Quantitative Biology , Peking University , Beijing 100871 , China
| | - Luhua Lai
- Peking-Tsinghua Center for Life Sciences , Peking University , Beijing 100871 , China . .,BNLMS , State Key Laboratory for Structural Chemistry of Unstable and Stable Species , College of Chemistry and Molecular Engineering , Peking University , Beijing 100871 , China.,Center for Quantitative Biology , Peking University , Beijing 100871 , China
| |
Collapse
|